医学
麻醉
术后恶心呕吐
舒芬太尼
类阿片
恶心
围手术期
呕吐
全身麻醉
发作性谵妄
Pacu公司
镇静
外科
止吐药
七氟醚
内科学
受体
作者
Christina Massoth,Judith Schwellenbach,Khaschayar Saadat-Gilani,Raphael Weiß,Daniel M. Pöpping,Mira Küllmar,Manuel Wenk
标识
DOI:10.1016/j.jclinane.2021.110437
摘要
Opioid-free anaesthesia may enhance postoperative recovery by reducing opioid-related side effects such as nausea, hyperalgesia or tolerance. The objective was to investigate the impact of multimodal opioid-free general anaesthesia on postoperative nausea, vomiting, pain and morphine consumption compared to the traditional opioid-based approach.This study was conducted as a prospective parallel-group randomised controlled trial.Perioperative Care.152 adult women undergoing elective inpatient gynaecological laparoscopy.Patients were randomly assigned for opioid-free anaesthesia (Group OF) with dexmedetomidine, esketamine and sevoflurane or to have opioid-based anaesthesia (Group C) with sufentanil and sevoflurane.Primary outcome was the occurrence of nausea within 24 h after surgery. Patients were assessed for the incidence and severity of PONV, postoperative pain and morphine consumption and recovery characteristics.Patients in both groups had comparable clinical and surgical data. 69.7% of patients in the control group and 68.4% of patients in the opioid-free group met the primary endpoint (OR 1.06, 95% Confidence Interval (CI) (0.53; 2.12) p = 0.86). The incidence of clinically important PONV defined by the PONV impact scale was 8.1% (Group C) vs 10.5% (OF); p = 0.57). Antiemetic requirements, pain scores and morphine consumption were equivalent in both groups. Postoperative sedation was significantly increased in group OF (p < 0.001), and the median length of stay at the post-anaesthesia care unit was 69.0 min (46.5-113.0) vs 50.0 (35.3-77.0) minutes in the control group (p < 0.001).Opioid-free multimodal general anaesthesia is feasible but did not decrease the incidence of PONV, or reduce pain scores and morphine consumption compared to an opioid-containing anaesthetic regimen.
科研通智能强力驱动
Strongly Powered by AbleSci AI